Federal News

Displaying results 1-10 (of 72)
 |<  < 1 2 3 4 5 6 7 8  >  >| 

Express Scripts Announces New Formulary Design Option

This week, Express Scripts announced that it would provide clients with the ability to opt for its new National Preferred Flex Formulary Design. As opposed to favoring drugs that garner the most rebate dollars, the new benefit design intends to favor drugs that have lower list prices to begin with.

READ MORE

CSRO Discusses New Drug Payment Model with Key Agency Officials

Last week, CSRO’s Past President and National Advocacy Chair, Michael Schweitz, MD, participated in one-on-one discussions with Centers for Medicare and Medicaid Services (CMS) Administrator Seema Verma and Special Advisor to the Administrator Jeet Guram, MD, to discuss details about the Trump Administration’s potential International Pricing Index Model for Medicare Part B Drugs.

READ MORE

CSRO Discusses Part B and D with CMS

Members of CSRO’s executive board recently met with CMS to discuss Part B and D drug pricing. Doctors Michael Schweitz, Madelaine Feldman, Greg Schimizzi traveled to D.C. to present CSRO’s feedback on recent proposals and provide rheumatology’s perspective on the programs.

READ MORE

CSRO Responds to RFI Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs

CSRO has submitted their comments regarding the Request for Information (RFI) by the Department of Health and Human Services.

READ MORE

CSRO Presents on PBMs at the Board of Hispanic Caucus Chairs Conference

CSRO Vice President, Dr. Madelaine Feldman recently presented on Pharmacy Benefit Managers and utilization management tools at the Board of Hispanic Caucus Chairs meeting in Las Vegas, Nevada.

READ MORE

FDA Biosimilars Educational Material

To date, the U.S. Food and Drug Administration (FDA) has approved seven biosimilars, and some are already on the market. As the biosimilars market continues to grow, there are still a lot of questions from both patients and physicians about these important new treatment options.

READ MORE

CSRO Opposes Efforts to Establish a National Benchmark Plan Standard for Prescription Drugs

The CSRO has submitted comments to CMS expressing concerns with their intent to establish a national benchmark plan standard for prescription drugs in future years.

READ MORE

CSRO Responds to Federal Innovation Center RFI

The CSRO has responded to a request for information (RFI) from the Innovation Center as the federal agency plans for a new direction. The comments submitted focus on specific issues that uniquely impact practicing rheumatologists and the patients they serve.

READ MORE

CSRO Presents at the Patient and Health Advocacy Bio Summit

Dr. Madelaine Feldman traveled to Washington D.C. recently to attend the Patient and Health Advocacy Bio Summit.

READ MORE

CSRO Submits Comments to CMS on Proposed Revisions for 2018

As patient and physician advocates, the CSRO actively monitors regulatory changes that affect physician’s ability to effectively treat their patients and operate their practices. As such, the CSRO took note of and discussed revisions proposed by the Center for Medicare and Medicaid Services for 2018.

READ MORE

Displaying results 1-10 (of 72)
 |<  < 1 2 3 4 5 6 7 8  >  >|